

1 **Title**

2 A deep intronic variant in *MME* causes autosomal recessive Charcot-Marie-Tooth neuropathy
3 through aberrant splicing.

4 **Authors**

5 Bianca R Grosz^{1,2}, Jevin M Parmar^{3,4}, Melina Ellis^{1,2}, Samantha Bryen^{5,6}, Cas Simons^{5,6},
6 Andre L.M. Reis^{5,7,8}, Igor Stevanovski^{5,7}, Ira W. Deveson^{5,7,8}, Garth Nicholson^{2,11}, Nigel
7 Laing³, Mathew Wallis^{9,10}, Gianina Ravenscroft³, Kishore R. Kumar^{2,11,12,13}, Steve Vucic^{2,14},
8 Marina L Kennerson^{1,2,11}

9 **ORCID:**

10 Bianca R Grosz: 0000-0002-6926-0551

11 Jevin Parmar: 0000-0003-1864-8094

12 Melina Ellis: 0000-0002-8542-048X

13 Samantha Bryen: 0000-0002-4140-8622

14 Cas Simons: 0000-0003-3147-8042

15 Andre L.M Reis: 0000-0002-7300-1157

16 Igor Stevanovski: 0000-0002-7713-1979

17 Ira W Deveson: 0000-0003-3861-0472

18 Mathew Wallis: 0000-0002-5441-1732

19 Garth A Nicholson: 0000-0001-9694-066X

20 Nigel Laing: 0000-0001-5111-3732

21 Gianina Ravenscroft: 0000-0003-3634-211X

22 Kishore R Kumar: 0000-0003-3482-6962

23 Marina L Kennerson: 0000-0003-3332-5074

24

25 Affiliations:

- 26 1. Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, NSW 2139,
27 Australia
- 28 2. The University of Sydney, Camperdown, NSW, 2050, Australia
- 29 3. Rare Disease Genetics and Functional Genomics Research Group, Harry Perkins
30 Institute of Medical Research, QEII Medical Centre, Nedlands, Western Australia,
31 6009, Australia
- 32 4. Centre for Medical Research, Faculty of Health and Medical Sciences, The University
33 of Western Australia, Perth, WA 6009, Australia
- 34 5. Centre for Population Genomics, Garvan Institute of Medical Research, and UNSW
35 Sydney, Sydney, NSW, Australia
- 36 6. Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne,
37 VIC, Australia
- 38 7. Genomics and Inherited Disease Program, Garvan Institute of Medical Research,
39 Sydney, NSW, Australia.
- 40 8. Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
- 41 9. Tasmanian Clinical Genetics Service, Tasmanian Health Service, Hobart, TAS,
42 Australia.
- 43 10. School of Medicine and Menzies Institute for Medical Research, University of
44 Tasmania, Hobart, TAS, Australia.
- 45 11. Molecular Medicine Laboratory and Neurology Department, Concord Repatriation
46 General Hospital, Hospital Rd, Concord, NSW, 2139, Australia
- 47 12. Translational Neurogenomics Group, Genomic and Inherited Disease Program, The
48 Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010,
49 Australia
- 50 13. St Vincent's Healthcare Campus, Faculty of Medicine, UNSW Sydney, Level 5, De
51 Lacy Building, St Vincent's Hospital, Darlinghurst, NSW, 2010, Australia.
- 52 14. Brain and Nerve Research Centre, The University of Sydney, Sydney, NSW 2139,
53 Australia

54

55

56

57 Abstract

58 **Background:** Loss-of-function variants in *MME* (membrane metalloendopeptidase) are a
59 known cause of recessive Charcot-Marie-Tooth Neuropathy (CMT). A deep intronic variant,
60 *MME* c.1188+428A>G (NM_000902.5), was identified through whole genome sequencing
61 (WGS) of two Australian families with recessive inheritance of axonal CMT using the seqr
62 platform. *MME* c.1188+428A>G was detected in a homozygous state in Family 1, and in a
63 compound heterozygous state with a known pathogenic *MME* variant (c.467del;
64 p.Pro156Leufs*14) in Family 2.

65 **Aims:** We aimed to determine the pathogenicity of the *MME* c.1188+428A>G variant
66 through segregation and splicing analysis.

67 **Methods:** The splicing impact of the deep intronic *MME* variant c.1188+428A>G was
68 assessed using an *in vitro* exon-trapping assay.

69 **Results:** The exon-trapping assay demonstrated that the *MME* c.1188+428A>G variant
70 created a novel splice donor site resulting in the inclusion of an 83 bp pseudoexon between
71 *MME* exons 12 and 13. The incorporation of the pseudoexon into *MME* transcript is predicted
72 to lead to a coding frameshift and premature termination codon (PTC) in *MME* exon 14
73 (p.Ala397ProfsTer47). This PTC is likely to result in nonsense mediated decay (NMD) of
74 *MME* transcript leading to a pathogenic loss-of-function.

75 **Interpretation:** To our knowledge, this is the first report of a pathogenic deep intronic *MME*
76 variant causing CMT. This is of significance as deep intronic variants are missed using whole
77 exome sequencing screening methods. Individuals with CMT should be reassessed for deep
78 intronic variants, with splicing impacts being considered in relation to the potential
79 pathogenicity of variants.

80 Key Words (up to 5): Charcot-Marie-Tooth disease, splicing, *MME*, recessive, deep intronic

81 Introduction

82 Charcot-Marie-Tooth neuropathy (CMT) is the most common inherited peripheral
83 neuropathy, affecting 1/2500 individuals¹. CMT is characterized by progressive length-
84 dependent loss of peripheral motor and sensory nerves, resulting in distal muscle weakness
85 and sensory symptoms². Patients are broadly divided into subtypes based on whether nerve
86 conduction studies (NCS) indicating demyelinating (CMT1) or axonal (CMT2) forms of the
87 disease. Recessive loss-of-function variants in the membrane metalloendopeptidase (*MME*)
88 gene have been previously reported to cause axonal Charcot-Marie-Tooth neuropathy type 2T
89 (CMT2T; OMIM: #617017)³⁻¹¹. *MME* encodes for neprilysin, a widely expressed membrane-
90 bound metallopeptidase that has a key role in neuropeptide processing¹². A significant portion
91 of patients with axonal CMT remain genetically undiagnosed¹³⁻¹⁷, indicating that further
92 disease-causing genes and pathogenic variants in known genes are yet to be identified.

93 Splicing variants are increasingly being recognized as a cause of Mendelian disease^{18,19}. The
94 precise removal of introns (non-coding regions) and inclusion of exons (coding regions) in
95 the final mature mRNA relies on the spliceosome and auxiliary splicing factors recognizing
96 specific sequence motifs, such as the 5' donor splice site and 3' acceptor splice site. Splice-
97 altering variants can weaken or abolish recognition of the correct splice sites, or alternatively
98 strengthen or create cryptic splice sites that mimic consensus splicing sequences²⁰. These
99 variants typically lead to one or more mis-splicing events that result in the skipping of partial
100 or complete exons, and/or the retention of partial or complete introns²¹⁻⁴². Pathogenic
101 splicing variants have been found in several CMT genes including *MPZ*^{21,30,39,40},
102 *MFN2*^{22,30,31}, *LRSAMI*²³, *IGHMBP2*²⁴, *INF2*²⁵, *MCM3AP*²⁶, *SH3TC2*^{30,32,38}, *GDAP1*^{27,42},
103 *SBF1*²⁸, *NDRG1*³⁷, and *FGD4*²⁹. Variants affecting canonical splice donor and acceptor sites
104 have also been described in *MME*^{4,41}.

105 Exon-trapping, also known as a mini-gene assay, is an *in vitro* technique used to identify
106 exons in a genomic region of interest⁴³. This is of particular use when relevant patient tissue
107 is unavailable or when relevant transcripts may be unstable or degraded by nonsense
108 mediated decay (NMD)⁴⁴. The genomic region of interest is cloned into an exon-trapping
109 vector between two known exons. This exon-trapping vector is transfected into a cell line
110 where it is transcribed and undergoes a series of post-transcriptional processes that include
111 pre-mRNA splicing to create mature mRNA. This mRNA consists of the ‘trapped’ exons of
112 the genomic region of interest flanked by the known exons, which can then be Sanger
113 sequenced to characterize the ‘trapped’ exons. Comparison of ‘trapped’ exons between wild
114 type and variant genomic sequences can also indicate if a candidate variant affects splicing^{45–}
115 ⁵¹. The well-validated exon-trapping vector pSpliceExpress⁵² consists of known exons of the
116 rat insulin gene, *Ins2*, and has been used previously to determine the splicing impacts of
117 multiple pathogenic variants in Mendelian disease^{45–51}.

118 Here we report a deep intronic variant in *MME* [chr3:155142758A>G (hg38); *MME*
119 c.1188+428A>G], found in a recessive state in two Australian families. Exon-trapping
120 revealed that this variant creates a novel splice donor site in *MME* intron 12 (NM_000902.5)
121 which, along with a preceding existing cryptic splice acceptor site, results in the
122 incorporation of an 83 bp pseudoexon in the *MME* transcript [chr3:155,142,675-155,142,757
123 (hg38); r.1188_1189ins[1188+345_1188+427]]. The coding frameshift caused by this
124 pseudoexon leads to a PTC in exon 14 and likely NMD of the *MME* transcript
125 (p.Ala397ProfsTer47), resulting in a loss of *MME* function.

126

127 Materials and Methods:

128 Subjects

129 Members of Family 1 were recruited and informed consent was obtained for this study using
130 protocols approved by the Sydney Local Health District Human Ethics Research Committee
131 (2019/ETH07839). Recruitment and informed consent for the proband of Family 2 was
132 approved by the Human Research Ethics Committee of the Royal Melbourne Hospital
133 (HREC/16/MH/251).

134 Variant Detection

135 Genomic DNA for Family 1 was extracted from peripheral blood using the PureGene Kit
136 (Qiagen) following the manufacturer's instructions. WGS for two individuals in Family 1
137 (V:1 and V:3) was outsourced to the Garvan Sequencing Platform. Paired-end sequencing
138 reads of 150 base pairs were generated using the Illumina NovaSeq 6000 sequencing
139 machine, with 30-fold average read depth.

140 In Family 2, genomic DNA for the proband was extracted at the Department of Diagnostic
141 Genomics (PathWest, Perth, Australia) using the QIASymphony^{SP} machine and
142 QIASymphone® DSP DNA Midi Kit. The proband underwent WGS at the Australian
143 Genomics Research Facility (AGRF), Melbourne, following GATK4 best-practices. Paired-
144 end sequencing reads of 150 base pairs were generated using the Illumina NovaSeq 6000
145 sequencing machine, with 30-fold average read depth. Parental DNA was not available for
146 sequencing.

147 WGS data processing was performed at the Centre for Population Genomics (CPG) following
148 the DRAGEN GATK best practices pipeline. Reads were aligned to the hg38 reference
149 genome using Dragmap (v1.3.0). Cohort-wide joint calling of single nucleotide variants
150 (SNVs) and small insertion/deletion (indel) variants was performed using GATK

151 HaploTypeCaller (v4.2.6.1) with “--dragen-mode” enabled. Sample sex and relatedness
152 quality checks were performed using Somalier (v0.2.15)⁵³. Variants were annotated using
153 VEP 105, and loaded into the web-based variant filtration platform, seqr⁵⁴. A WGS search
154 was conducted using the seqr⁴⁵ platform for low minor allele frequency (<0.01) variants in
155 CMT-related genes, for both Family 1 and 2 [gene list- Hereditary
156 Neuropathy_CMT_IsolatedAndComplex (Version 2.14)⁵⁵]. Additionally, variants were
157 analyzed by the CPG Automated Interpretation Pipeline (AIP,
158 <https://github.com/populationgenomics/automated-interpretation-pipeline>). *In silico* splicing
159 analysis was conducted using SpliceAI⁵⁶.

160 Segregation Analysis

161 The *MME* c.1188+428A>G variant in Family 1 and Family 2 was amplified using primers
162 that spanned *MME* intron 12 (5'-CTCAGCCGAACCTACAAGGA-3'; 5'-
163 GCAAATGCTGCTTCCACAT-3') to produce a 1264 bp amplicon [chr3:155,142,289-
164 155,143,552 (hg38)]. An internal sequencing primer was used (5'-
165 CTGTGTTAAAAGTAATTTTCGGGG-3') and the amplicon was Sanger sequenced. The
166 *MME* c.467del variant in Family 2 was amplified (5'-GCAGAGCCGTATGCATCACT-3';
167 5'-TTCAGCTGTCCAAGAAGCACC-3'). A 717bp amplicon was produced
168 [chr3:155,116,171-155,116,887 (hg38)], which was subsequently Sanger sequenced.

169

170 Sanger Sequencing

171 For Family 1, PCR amplicons were sent to Garvan Molecular Genetics, Garvan Institute
172 (Sydney, Australia) for Sanger sequencing using BigDye Terminator cycle sequencing
173 protocols. For Family 2, proband PCR amplicons were Sanger sequenced at AGRF, Perth
174 using BigDye Terminator sequencing protocols. Sequences were visualized and analyzed
175 using Snapgene Software version 7.1 (www.snapgene.com).

176

177 Oxford Nanopore Technologies (ONT) Long Read Sequencing

178 High molecular weight (HMW) DNA samples of the Proband in Family 2 were transferred to
179 the Garvan Sequencing Platform for targeted long-read sequencing analysis on ONT
180 instruments. Prior to ONT library preparations, DNA was sheared to ~20-25 kb fragment size
181 using a MegaRuptor 3 instrument and visualized post-shearing on an Agilent FemtoPulse.

182 Sequencing libraries were prepared from ~3-5 µg of HMW DNA, using native library prep
183 kit SQK-LSK114, according to manufacturer's instructions. Each library was loaded onto a
184 R10.4.1 flow cell and sequenced on a PromethION device with live target selection/rejection
185 executed by the ReadFish software package⁵⁷. Detailed descriptions of software and hardware
186 configurations used for ReadFish are provided in a previous publication⁵⁸. Samples were run
187 for a maximum duration of 72 h, with nuclease flushes and library reloading performed at
188 approximately 24- and 48-h timepoints for targeted sequencing runs, to maximize sequencing
189 yield. Raw ONT sequencing data was converted to BLOW5 format⁵⁹ using slow5tools
190 (v.0.3.0)⁶⁰ then base-called using Guppy (v6). Resulting FASTQ files were aligned to the
191 hg38 reference genome using minimap2 (v2.14-r883)⁶¹. Variants were called using clair3⁶²,
192 phased using Whatshap⁶³ and visualized using the Integrative Genomics Viewer (IGV,
193 v2.17.3)⁶⁴.

194 Cell Culture

195 The human HeLa cervical epithelial cell line (ATCC) was maintained in Dulbecco's
196 Modified Eagle's Medium (DMEM)(Gibco) containing 10% (v/v) fetal bovine serum (FBS)
197 (Gibco), +100 U/mL penicillin (Gibco), and 100 µg/mL streptomycin (Gibco) at 37°C in
198 humidified air and 5% CO₂.

199 Cloning Procedures

200 The region surrounding *MME* c.1188+428A>G [chr3:155,141,790-155,143,755 (hg38)] was
201 amplified from the genomic DNA of a heterozygous carrier of the c.1188+428A>G variant,
202 using *attB* adapter primers (5'-AAAAAGCAGGCTTCGCTCTTAAATGGTTGGCTT-3'; 5'-
203 AGAAAGCTGGGTAAGTACTAGACTCTTGGGGAAGGC -3'). The *MME* amplicon was then
204 cloned into the exon-trapping pSpliceExpress vector between flanking *Ins2* exons using a
205 two-step Gateway cloning BP reaction (ThermoFisher). pSpliceExpress was a gift from
206 Stefan Stamm (Addgene plasmid #32485)⁵². The pSpliceExpress-*MME* clones were then
207 Sanger sequenced to verify the correct insertion of *MME* and to determine the
208 c.1188+428A>G genotype of each clone (as the genomic DNA template was heterozygous
209 for the variant).

210 *In vitro* exon-trapping

211 HeLa cells were grown to approximately 70% confluence in a 6-well plate. HeLa cells were
212 separately transfected with either 2 µg of pSpliceExpress-*MME*_{WT} or 2 µg of pSpliceExpress-
213 *MME*_{c.1188+428A>G} using Lipofectamine 3000 (ThermoFisher). RNA extraction was performed
214 48 h following transfection using the RNEasy Mini Kit (Qiagen), and reverse-transcribed
215 template was prepared using the iScript cDNA Synthesis Kit (Bio-Rad). PCR amplification
216 of cDNA was conducted using primers designed to anneal to the flanking *Ins2* exons (5'-
217 CAGCACCTTTGTGGTTCTCA-3'; 5'-CAGTGCCAAGGTCTGAAGGT-3'). The RT-PCR
218 amplicons were size fractionated using a 1.5% w/v agarose gel. The largest amplicon for each
219 vector was gel-purified using Isolate II PCR and Gel Kit (Bioline) for Sanger Sequencing.

220 *In silico* splicing analysis of reported *MME* variants

221 All reported *MME* variants in gnomAD v.4.0.0 were detected by searching the gnomAD
222 browser for the genomic region corresponding with the *MME* gene; '3-155024124-
223 155183704'(hg38). The *MME* variants reported in gnomAD were then exported using the

224 'Export Variants to CSV' function. The consequences of the variants were described by
225 gnomAD using the Variant Effect Predictor (VEP) annotation based on the most deleterious
226 predicted functional effect of each variant⁶⁵. These variants were then filtered for a minor
227 allele frequency (MAF) <0.01 and a maximum SpliceAI Δ score >0.8 (high precision splicing
228 change prediction⁶⁶) as annotated by gnomAD.

229

230

231

232 Results:

233 Clinical Phenotypes

234 Family 1 consists of four affected siblings from a consanguineous family of European (non-
235 Finnish) background (Figure 1a). The phenotype was consistent with a generalized
236 sensorimotor axonal neuropathy and sensory ataxia without cerebellar signs (Table 1), and
237 was confirmed with NCS for individuals V:1 and V:6 (Table 2). Affected individuals had
238 previously undergone diagnostic and research whole exome sequencing with negative results.

239 Family 2 consists of one affected female born to a healthy, non-consanguineous couple
240 (Figure 1b). Neurological examination revealed mild distal upper limb weakness and
241 moderate distal lower limb weakness (Table 1). NCS showed evidence of an axonal
242 sensorimotor neuropathy (Table 2). Bilateral MRI of the thighs and calves showed muscle
243 atrophy (Supplementary Figure 1).

244 Genetic Analysis

245 WGS screening using the seqr platform in Family 1 revealed a single homozygous variant in
246 two affected individuals (V:1 and V:3), *MME* c.1188+428A>G (NM_000902.5). This variant
247 was reported in dbSNP build 155⁶⁷ (rs61758195), with a low MAF in gnomAD v4.0.0⁶⁸
248 (10/152120), All of Us (35/490,748)⁶⁹, and TOPMED⁷⁰ (15/264290). No homozygous
249 individuals were reported in gnomAD, All of Us, or TOPMED. SpliceAI predicted that *MME*
250 c.1188+428A>G could create a strong novel splice donor site (Score 0.97; where a SpliceAI
251 score above 0.8 is considered a ‘high precision’ predicted splice variant⁵⁶). This in turn
252 strengthened the SpliceAI prediction for a cryptic splice acceptor site 83 bp upstream of the
253 novel splice donor site (Score 0.99).

254 Segregation analysis in Family 1 confirmed the biallelic inheritance of the *MME*
255 c.1188+428A>G variant segregated with the CMT phenotype (Figure 1a). Sanger
256 sequencing of DNA from available individuals showed that all affected individuals were
257 homozygous for the *MME* c.1188+428A>G variant and unaffected individuals were carriers
258 (Supplementary Figure 2).

259 WGS screening using the seqr platform and AIP was conducted in the proband of Family 2
260 (II:1). The *MME* c.1188+428A>G variant was detected in a compound heterozygous state
261 with a second *MME* variant (*MME* c.467del; p.Pro156Leufs*14), which has previously been
262 reported as pathogenic⁴¹ (Figure 1b). Sanger sequencing validated the presence of each *MME*
263 variant in the index individual (Supplementary Figure 3). As parental DNA was unavailable,
264 ONT long-read sequencing was conducted to phase the heterozygous *MME* variants in the
265 proband (Figure 1c-d). ONT long-read sequencing confirmed that *MME* c.1188+428A>G
266 (boxed red in Figure 1c) and c.467del (boxed red in Figure 1d) were present on alternative
267 haplotypes (hap-1: red, hap-2: blue) and therefore were in *trans* in the proband.

268 *In vitro* exon-trapping of *MME*-pSpliceExpress vectors

269 Two separate exon-trapping pSpliceExpress vectors were generated to assess the *in vitro*
270 splicing impact of the *MME* c.1188+428A>G variant: pSpliceExpress-*MME*_{WT} (wild-type)
271 and pSpliceExpress-*MME*_{c.1188+428A>G} (variant). A schematic of the constructs and relevant
272 SpliceAI scores are shown in Figure 2a. RT-PCR products produced following transfection of
273 these vectors were analyzed using gel electrophoresis (Figure 2b), which revealed a visible
274 size difference between the wild-type (381 bp) and *MME* c.1188+428A>G amplicons (464
275 bp). The gel-purified amplicons were Sanger sequenced and the sequencing was aligned to
276 the WT *MME* mRNA sequence. The sequenced products showed that the pSpliceExpress-
277 *MME*_{WT} produced a transcript that was correctly spliced between *MME* exon 12 and 13
278 (Figure 2c). In contrast, exon-trapping of the pSpliceExpress-*MME*_{c.1188+428A>G} vector showed
279 that an 83 bp pseudoexon had been spliced between *MME* exon 12 and 13 (Figure 2d). A
280 BLAT search⁷¹ using the sequence of the trapped pseudoexon revealed alignment to the
281 intronic region directly upstream of the *MME* c.1188+428A>G variant [chr3:155,142,675-
282 155,142,757 (hg38)]. This suggests that the *MME* c.1188+428A>G variant creates a novel
283 splice donor site leading to the aberrant inclusion of 83 bp of intronic *MME* sequence in the
284 final spliced transcript, as predicted by SpliceAI. Prediction of the novel *MME* coding
285 sequence caused by the introduction of the pseudoexon showed that a PTC was generated in
286 exon 14 (p.Ala397ProfsTer47) at genomic position chr3:155,144,368 (hg38)(Supplementary
287 Figure 4). This PTC likely leads to NMD of the *MME* transcript.

288 *In silico* splicing analysis of *MME* variants

289 All reported *MME* variants in gnomAD v.4.0.0 were assessed using the integrated SpliceAI
290 scores to determine if splicing variants in *MME* were a likely underrecognized cause of
291 disease. There were 37,264 total variants reported in *MME* in gnomAD, of which 35,673
292 variants had a MAF <0.01. Of these, 88 variants had a maximum SpliceAI Δ score above 0.8

293 (Supplementary Table 1). There were no homozygotes reported for any of the 88 *MME*
294 putative splicing variants. The majority of these predicted splicing variants were predicted to
295 directly change either the canonical splice donor sites (26/88) or canonical splice acceptor
296 sites (30/88) of *MME*, including an inframe deletion (c.1317_1317+2del) and a frameshift
297 variant (c.957+1del). An additional nine variants were predicted to affect a splicing region,
298 including one which is also annotated as a synonymous variant (c.1188G>A; p.Lys396Lys).
299 Nine missense variants (p.Asp209Gly, p.Ile217Ser, p.Glu282Val, p.Arg365Ile, p.Ser436Gly,
300 p.Asp533Gly, p.Ile553Val, p.Val554Phe, p.Gln692Arg) and a synonymous variant
301 (p.Gly417Gly) were also predicted to alter splicing. Twelve variants were annotated as
302 ‘intron variants’, of which two could be considered ‘deep intronic’ variants
303 (c.1188+428A>G, described in this manuscript, and c.197-9871A>G). Interestingly, further
304 analysis using SpliceAI demonstrated that *MME* c.197-9871A>G was predicted to create a
305 splice donor site (Score 0.81) and strengthen an upstream cryptic splice acceptor site (Score
306 0.81) in a similar manner to c.1188+428A>G, thereby possibly creating an in-frame 96 bp
307 pseudoexon.

308

309

310 Discussion

311 Here we report a deep intronic variant, *MME* c.1188+428A>G causing recessive CMT2T in
312 two unrelated Australian families. This variant results in a pseudoexon that likely leads to
313 NMD of the *MME* transcript, resulting in a loss-of-function. This is in keeping with
314 previously reported *MME* variants which have broadly been characterised as ‘loss-of-
315 function’ variants. To our knowledge, this is the first report of a pathogenic deep intronic
316 variant in *MME*. Given that a significant portion of patients with axonal CMT remain
317 genetically undiagnosed¹³⁻¹⁷, it’s possible that deep intronic variants in *MME* explain a
318 portion of this diagnostic gap.

319 Individuals from Family 1 previously underwent both diagnostic WES and research WES,
320 and the proband in Family 2 previously underwent targeted gene panel testing (PathWest
321 neuro v3). These testing methods did not capture deep intronic regions and returned negative
322 results. However, deep intronic regions have previously been shown to have a higher
323 prevalence of variants than coding regions and canonical splice sites⁷². Our findings suggest
324 that intronic SNPs should be analyzed to determine if they impact splicing before they are
325 dismissed as benign. Detection and functional validation of deep intronic variants has
326 previously been shown to increase diagnostic rates in other Mendelian diseases including X-
327 linked Alport syndrome⁷³, inherited retinal disorders^{74,75}, and dystrophinopathy^{76,77}.
328 Pathogenic deep intronic variants, such as described here, are likely to be underreported
329 amongst CMT-causing genes due to a lack of detection by WES and targeted gene panels,
330 and a lack of functional investigation upon detection.

331 The *MME* c.1188+428A>G variant was reported in multiple different genetic ancestry groups
332 in gnomAD v.4.0.0⁶⁸, including in the European (Non-Finnish) (8/68008), African/African

333 American (1/41432), and ‘remaining’ (1/2092) ancestry groups. This was also reflected in the
334 ‘All of Us’ Research Program⁶⁹, which reported the *MME* c.1188+428A>G variant in the
335 African (2/107,888) and European populations (33/256,804). Whilst it is possible that *MME*
336 c.1188+428A>G represents a recurrent *de novo* variant, it is also likely that this variant has
337 persisted at low levels in the global population. As this variant is missed by WES and may
338 not be prioritised by variant-filtering approaches focusing on coding variants, this variant
339 may therefore represent an underappreciated cause of recessive CMT. This is further
340 supported by its detection in two Australian CMT families who are not known to be related.

341 Whilst the predicted splicing variants reported in *MME* are individually rare, we have
342 described eighty-eight variants in gnomAD that are predicted by SpliceAI to alter splicing.
343 Nine of these variants were annotated as missense variants, and one was a synonymous
344 change. This is of note as these ‘missense’ variants are often assumed to result in a single
345 amino acid change, and synonymous variants are often considered functionally neutral, with
346 their effect on splicing typically not assessed⁷⁸. Our results suggest that the discovery of any
347 of these eighty-eight variants in a homozygous or compound heterozygous state in an
348 individual with CMT should prompt further functional investigation of their effect on splicing
349 of the *MME* transcript.

350 Prior to functional validation, *MME* c.1188+428A>G was considered a variant of uncertain
351 significance (VUS) according to American College of Medical Genetics and Genomics
352 (ACMG) criteria⁷⁹ (BP4, PM2, PM3, PP1). However, the functional evidence generated by
353 the splicing assay now allows for the addition of PVS1 (null variant in a gene where loss-of-
354 function is a known mechanism of disease) and PS3 (well-established *in vitro* or *in vivo*
355 functional studies supportive of a damaging effect on the gene or gene product) criteria. This
356 allows reclassification of the variant as ‘pathogenic’. Therefore, this work demonstrates the

357 importance of functional validation to confirm the effect of candidate variants on splicing to
358 increase diagnostic rates for those with inherited disease.

359 Previously described homozygous *MME* patients typically have a phenotype consistent with
360 late-onset axonal neuropathy. In contrast, three of the four affected siblings in Family 1
361 described childhood onset and the proband of Family 2 described symptom onset in early
362 adulthood. It has also previously been reported that heterozygous *MME* variants can cause
363 spinocerebellar ataxia type 43 (SCA43)⁸⁰ as well as autosomal dominant CMT³. However,
364 the individuals in Family 1 who were *MME* c.1188+428A>G heterozygotes were all
365 clinically assessed as neurologically normal, including an individual who is in their seventh
366 decade. Homozygous affected individuals in Family 1 were noted to have a sensory ataxia
367 rather than cerebellar ataxia, although MRI brain studies were not conducted. Therefore, our
368 findings here do not support a role for *MME* c.1188+428A>G to cause SCA43 or autosomal
369 dominant CMT, and further expand the phenotype of recessive CMT2T.

370 Understanding the specific effects of splice-affecting variants is crucial for developing
371 potential therapeutic strategies. Antisense oligonucleotides (ASOs) that modulate splicing are
372 an active area of research, including individualized approaches to treat rare genetic
373 diseases⁸¹⁻⁸³. Several antisense nucleotides that modify splicing have been approved by the
374 United States Food and Drug Administration and have resulted in marked improvements in
375 clinical outcomes in those with genetic diseases⁸⁴⁻⁹⁴. An FDA-approved “n-of-1” ASO,
376 milasen, successfully blocked pathogenic pseudoexon inclusion in *MFSD8* in a patient with
377 neuronal ceroid lipofuscinosis type 7⁹⁴. ASOs which block pathogenic pseudoexons, such as
378 that created by *MME* c.1188+428A>G, have also been described in *in vivo* preclinical
379 models^{93,95-99}. As such, individuals with the *MME* c.1188+428A>G variant may represent a

380 form of CMT that is treatable through personalized ASO therapy and warrants further
381 investigation.

382

383 Acknowledgements

384 This work was funded by the Medical Research Future Fund (MRFF) Genomics Health
385 Futures Mission (APP2007681). JMP is supported by the Australian Government Research
386 Training Program. IWD was supported by MRF2025138 & MRF2023126. Genomic analysis
387 was supported by the Centre for Population Genomics (Garvan Institute of Medical Research
388 and Murdoch Children's Research Institute) and was funded in part by a National Health and
389 Medical Research Council investigator grant (2009982) and the Medical Research Future
390 Fund (MRFF) Genomics Health Futures Mission (2008820).

391 **Figure Legends:**

392 **Figure 1: The *MME* c.1188+428A>G (NM_000902.5) variant segregates with recessive**
393 **CMT in two families.** A) Family 1 pedigree showing the associated genotypes for the *MME*
394 c.1188+428A>G (NM_000902.5) variant. Affected individuals in the fifth generation are
395 homozygous (G/G). Unaffected individuals in the fifth (V) and sixth (VI) generation are
396 heterozygous (A/G). Squares represent males and circles represent females, solid symbol
397 denotes affected individual. The double line in the fourth (IV) generation indicates a
398 consanguineous relationship. The *MME* c.1188+428 genotype is denoted beneath individuals
399 who underwent Sanger sequencing, with the pathogenic 'G' allele in red text. B) A pedigree
400 showing the associated genotypes for *MME* c.1188+428A>G and *MME* c.467del in the index
401 individual in Family 2. C-D) Haplotype phasing showed that the c.1188+428A>G (C) and
402 c.467del (D) variants were present on alternative haplotypes (light red and light blue), thus
403 inherited *in trans* in the proband of Family 2. Phased targeted ONT long-read sequencing
404 reads were visualized using the Integrative Genomics Viewer (IGV; v2.17.3).

405 **Figure 2. An exon-trapping assay was used to analyze splicing changes caused by the**
406 ***MME* c.1188+428A>G variant.** A) Schematic of the pSpliceExpress-*MME*_{WT} (wild-type)
407 and pSpliceExpress-*MME*_{c.1188+428A>G} (variant) constructs. Both constructs consisted of an
408 RSV LTR promoter region (blue) controlling transcription of a minigene of *MME* exons 12
409 and 13 (grey) flanked by *Ins2* exon 2 and *Ins2* exon 3 (black). The constructs differed in the
410 presence of either an A (wild type: green text) or a G allele (mutant: red text) at *MME*
411 c.1188+428A>G. i) The wild type sequence was not predicted to contain any strong splice
412 sites when assessed using SpliceAI, with a score of 0.11 for the acceptor site (purple text) and
413 0.00 for the donor site (green text). ii) SpliceAI predicted that the *MME* c.1188+428A>G
414 variant (red arrow) would create a strong splice donor site [Score: 0.97 (Δ 0.97); red text],
415 which then strengthened the prediction of a splice acceptor site 83 bp upstream [Score 0.99

416 ($\Delta 0.97$); purple text]. The predicted 83 bp pseudoexon sequence is capitalized and boxed in
417 red. B) The amplicon produced by the pSpliceExpress-*MME*_{c.1188+428A>G} vector (464 bp)
418 showed a visible increase in product size when compared to the amplicon produced by
419 pSpliceExpress-*MME*_{WT} (381 bp). The 158 bp RT-PCR product produced by both vectors
420 indicated splicing and ligation of the flanking *Ins2* exon 2 and exon 3. Lanes: L:
421 HyperLadder 100 bp (Bioline); WT: wild-type; NRTC: negative cDNA conversion control
422 (no reverse transcriptase). NTC: negative PCR reaction control (no cDNA template). C)
423 Sanger sequencing of the pSpliceExpress-*MME*_{WT} RT-PCR product confirmed correct
424 splicing between *MME* exon 12 and 13. D) Sanger sequencing of the pSpliceExpress-
425 *MME*_{c.1188+428A>G} RT-PCR product revealed the presence of a novel 83 bp pseudoexon (red)
426 between *MME* exon 12 and 13. Abbreviations: RSV LTR: Rous Sarcoma Virus Long
427 Terminal Repeat promoter; *Ins2*: rat preproinsulin 2 gene.

428

429

430 References

431

- 432 1. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. *Clin Genet.*
433 1974;6:98-118.
- 434 2. Szigeti K, Lupski JR. Charcot–Marie–Tooth disease. *European Journal of Human*
435 *Genetics.* 2009;17(6):703-710. doi:10.1038/ejhg.2009.31
- 436 3. Senderek J, Lassuthova P, Kabzińska D, et al. The genetic landscape of axonal
437 neuropathies in the middle-aged and elderly. *Neurology.* 2020;95(24).
438 doi:10.1212/WNL.0000000000011132
- 439 4. Higuchi Y. Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth
440 disease type 2. *Ann Neurol.* 2016;79:659-672.
- 441 5. Record CJ, Pipis M, Skorupinska M, et al. Whole genome sequencing increases the
442 diagnostic rate in Charcot-Marie-Tooth disease. *Brain.* Published online March 14,
443 2024. doi:10.1093/brain/awae064
- 444 6. Jamiri Z, Khosravi R, Heidari MM, Kiani E, Gharechahi J. A nonsense mutation in
445 <sc>MME</sc> gene associates with autosomal recessive late-onset
446 <sc>Charcot–Marie–Tooth</sc> disease. *Mol Genet Genomic Med.* 2022;10(5).
447 doi:10.1002/mgg3.1913
- 448 7. Taghizadeh S, Vazehan R, Beheshtian M, et al. Molecular Diagnosis of Hereditary
449 Neuropathies by Whole Exome Sequencing and Expanding the Phenotype Spectrum.
450 *Arch Iran Med.* 2020;23(7):426-433. doi:10.34172/AIM.2020.39
- 451 8. Ando M, Higuchi Y, Yuan J, et al. Comprehensive Genetic Analyses of Inherited
452 Peripheral Neuropathies in Japan: Making Early Diagnosis Possible. *Biomedicines.*
453 2022;10(7):1546. doi:10.3390/biomedicines10071546
- 454 9. Megarbane A, Bizzari S, Deepthi A, et al. A 20-year Clinical and Genetic
455 Neuromuscular Cohort Analysis in Lebanon: An International Effort. *J Neuromuscul*
456 *Dis.* 2022;9(1):193-210. doi:10.3233/JND-210652
- 457 10. Høyer H, Hilmarsen HT, Sunder-Plassmann R, et al. A polymorphic AT-repeat causes
458 frequent allele dropout for an MME mutational hotspot exon. *J Med Genet.*
459 2022;59(10):1024-1026. doi:10.1136/jmedgenet-2021-108281
- 460 11. Dupuis M, Raymackers JM, Ackermans N, Boulanger S, Verellen-Dumoulin C.
461 Hereditary axonal neuropathy related to MME gene mutation in a family with
462 fetomaternal alloimmune glomerulonephritis. *Acta Neurol Belg.* 2020;120(1):149-154.
463 doi:10.1007/s13760-020-01275-9
- 464 12. Krämer HH, He L, Lu B, Birklein F, Sommer C. Increased pain and neurogenic
465 inflammation in mice deficient of neutral endopeptidase. *Neurobiol Dis.*
466 2009;35(2):177-183. doi:10.1016/j.nbd.2008.11.002

- 467 13. Gemelli C, Geroldi A, Massucco S, et al. Genetic Workup for Charcot-Marie-Tooth
468 Neuropathy: A Retrospective Single-Site Experience Covering 15 Years. *Life (Basel)*.
469 2022;12(3). doi:10.3390/life12030402
- 470 14. Candayan A, Parman Y, Battaloğlu E. Clinical and Genetic Survey for Charcot-Marie-
471 Tooth Neuropathy Based on the Findings in Turkey, a Country with a High Rate of
472 Consanguineous Marriages. *Balkan Med J*. 2022;39(1):3.
473 doi:10.4274/BALKANMEDJ.GALENOS.2021.2021-11-13
- 474 15. Rudnik-Schöneborn S, Tölle D, Senderek J, et al. Diagnostic algorithms in Charcot-
475 Marie-Tooth neuropathies: experiences from a German genetic laboratory on the basis
476 of 1206 index patients. *Clin Genet*. 2016;89(1):34-43. doi:10.1111/cge.12594
- 477 16. Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients
478 enrolled in the Inherited Neuropathies Consortium natural history study: a cross-
479 sectional analysis. 2015;86(8):873-878. doi:10.1136/jnnp-2014-308826
- 480 17. Ma Y, Duan X, Liu X, Fan D. Clinical and mutational spectrum of paediatric Charcot-
481 Marie-Tooth disease in a large cohort of Chinese patients. *Front Genet*. 2023;14.
482 doi:10.3389/fgene.2023.1188361
- 483 18. Lord J, Baralle D. Splicing in the Diagnosis of Rare Disease: Advances and
484 Challenges. *Front Genet*. 2021;12:689892. doi:10.3389/fgene.2021.689892
- 485 19. Wang R, Helbig I, Edmondson AC, Lin L, Xing Y. Splicing defects in rare diseases:
486 transcriptomics and machine learning strategies towards genetic diagnosis. *Brief*
487 *Bioinform*. 2023;24(5). doi:10.1093/bib/bbad284
- 488 20. Anna A, Monika G. *Splicing Mutations in Human Genetic Disorders: Examples,*
489 *Detection, and Confirmation*. Vol 59. Springer Verlag; 2018:253-268.
490 doi:10.1007/s13353-018-0444-7
- 491 21. Corrado L, Magri S, Bagarotti A, et al. A novel synonymous mutation in the MPZ
492 gene causing an aberrant splicing pattern and Charcot-Marie-Tooth disease type 1b.
493 *Neuromuscular Disorders*. 2016;26(8):516-520. doi:10.1016/j.nmd.2016.05.011
- 494 22. Boaretto F, Vettori A, Casarin A, et al. Severe CMT type 2 with fatal encephalopathy
495 associated with a novel MFN2 splicing mutation. *Neurology*. 2010;74(23).
496 doi:10.1212/WNL.0b013e3181e240f9
- 497 23. Engeholm M, Sekler J, Schöndorf DC, et al. A novel mutation in LRSAM1 causes
498 axonal Charcot-Marie-Tooth disease with dominant inheritance. *BMC Neurol*.
499 2014;14(1):118. doi:10.1186/1471-2377-14-118
- 500 24. Cassini TA, Duncan L, Rives LC, et al. Whole genome sequencing reveals novel
501 *IGHMBP2* variant leading to unique cryptic splice site and Charcot-Marie-Tooth
502 phenotype with early onset symptoms. *Mol Genet Genomic Med*. 2019;7(6):e00676.
503 doi:10.1002/mgg3.676
- 504 25. Echaniz-Laguna A, Latour P, Echaniz-Laguna A, Latour P, Echaniz-Laguna A,
505 Latour P. A cryptic splicing mutation in the INF2 gene causing Charcot-Marie-Tooth

- 506 disease with minimal glomerular dysfunction. *Journal of the Peripheral Nervous*
507 *System*. 2019;24(1):120-124. doi:10.1111/jns.12308
- 508 26. Ylikallio E, Woldegebriel R, Tumiati M, et al. MCM3AP in recessive Charcot-Marie-
509 Tooth neuropathy and mild intellectual disability. *Brain*. 2017;140(8):2093-2103.
510 doi:10.1093/brain/awx138
- 511 27. Numakura C, Lin C, Ikegami T, Guldborg P, Hayasaka K. Molecular analysis in
512 Japanese patients with Charcot-Marie-Tooth disease: DGGE analysis for PMP22,
513 MPZ, and Cx32/GJB1 mutations. *Hum Mutat*. 2002;20(5):392-398.
514 doi:10.1002/humu.10134
- 515 28. Flusser H, Halperin D, Kadir R, Shorer Z, Shelef I, Birk OS. Novel SBF1 splice-site
516 null mutation broadens the clinical spectrum of Charcot-Marie-Tooth type 4B3
517 disease. *Clin Genet*. 2018;94(5):473-479. doi:10.1111/cge.13419
- 518 29. Hayashi M, Abe A, Murakami T, et al. Molecular analysis of the genes causing
519 recessive demyelinating Charcot-Marie-Tooth disease in Japan. *J Hum Genet*.
520 2013;58(5):273-278. doi:10.1038/jhg.2013.15
- 521 30. DiVincenzo C, Elzinga CD, Medeiros AC, et al. The allelic spectrum of Charcot-
522 Marie-Tooth disease in over 17,000 individuals with neuropathy. *Mol Genet Genomic*
523 *Med*. 2014;2(6):522-529. doi:10.1002/mgg3.106
- 524 31. Martikainen MH, Kytövuori L, Majamaa K. Novel mitofusin 2 splice-site mutation
525 causes Charcot-Marie-Tooth disease type 2 with prominent sensory dysfunction.
526 *Neuromuscular Disorders*. 2014;24(4):360-364. doi:10.1016/J.NMD.2014.01.007
- 527 32. Piscoquito G, Saveri P, Magri S, et al. Screening for SH3TC2 gene mutations in a
528 series of demyelinating recessive Charcot-Marie-Tooth disease (CMT4). *J Peripher*
529 *Nerv Syst*. 2016;21(3):142-149. doi:10.1111/jns.12175
- 530 33. Benedetti S, Previtali SC, Coviello S, et al. Analyzing histopathological features of
531 rare Charcot-Marie-Tooth neuropathies to unravel their pathogenesis. *Arch Neurol*.
532 2010;67(12):1498-1505. doi:10.1001/archneurol.2010.303
- 533 34. Li MY, Yin M, Yang L, et al. A novel splicing mutation in 5'UTR of GJB1 causes X-
534 linked Charcot—Marie—tooth disease. *Mol Genet Genomic Med*. 2023;11(3):e2108.
535 doi:10.1002/MGG3.2108
- 536 35. Boso F, Taioli F, Cabrini I, Cavallaro T, Fabrizi GM. Aberrant Splicing in GJB1 and
537 the Relevance of 5' UTR in CMTX1 Pathogenesis. *Brain Sci*. 2020;11(1):24.
538 doi:10.3390/brainsci11010024
- 539 36. Tomaselli PJPPJ, Rossor AM, Horga A, et al. Mutations in noncoding regions in GJB1
540 are a major cause of X-linked CMT. *Neurology*. 2017;88(15):1445-1453.
541 doi:10.1212/WNL.0000000000003819
- 542 37. Pravinbabu P, Holla V V, Phulpagar P, et al. A splice altering variant in NDRG1 gene
543 causes Charcot-Marie-Tooth disease, type 4D. *Neurol Sci*. 2022;43(7):4463-4472.
544 doi:10.1007/s10072-022-05893-4

- 545 38. Shchagina O, Orlova M, Murtazina A, Filatova A, Skoblov M, Dadali E. Evaluation of
546 Pathogenicity and Causativity of Variants in the MPZ and SH3TC2 Genes in a Family
547 Case of Hereditary Peripheral Neuropathy. *Int J Mol Sci.* 2023;24(12).
548 doi:10.3390/ijms24129786
- 549 39. Taioli F, Cabrini I, Cavallaro T, Simonati A, Testi S, Fabrizi GM. Déjerine-Sottas
550 syndrome with a silent nucleotide change of myelin protein zero gene. *Journal of the*
551 *Peripheral Nervous System.* 2011;16(1):59-64. doi:10.1111/j.1529-8027.2011.00319.x
- 552 40. Sabet A, Li J, Ghandour K, et al. Skin biopsies demonstrate MPZ splicing
553 abnormalities in Charcot-Marie-Tooth neuropathy 1B. *Neurology.* 2006;67(7):1141-
554 1146. doi:10.1212/01.wnl.0000238499.37764.b1
- 555 41. Lupo V. Characterising the phenotype and mode of inheritance of patients with
556 inherited peripheral neuropathies carrying MME mutations. *J Med Genet.*
557 2018;55:814-823.
- 558 42. Masingue M, Perrot J, Carlier RY, Piguët-Lacroix G, Latour P, Stojkovic T. WES
559 homozygosity mapping in a recessive form of Charcot-Marie-Tooth neuropathy
560 reveals intronic GDAP1 variant leading to a premature stop codon. *Neurogenetics.*
561 2018;19(2):67-76. doi:10.1007/s10048-018-0539-7
- 562 43. Duyk GM, Kim SW, Myers RM, Cox DR. Exon trapping: a genetic screen to identify
563 candidate transcribed sequences in cloned mammalian genomic DNA. *Proceedings of*
564 *the National Academy of Sciences.* 1990;87(22):8995-8999.
565 doi:10.1073/pnas.87.22.8995
- 566 44. Micale L, Morlino S, Schirizzi A, et al. Exon-Trapping Assay Improves Clinical
567 Interpretation of COL11A1 and COL11A2 Intronic Variants in Stickler Syndrome
568 Type 2 and Ootospondylomegaepiphyseal Dysplasia. *Genes (Basel).* 2020;11(12):1513.
569 doi:10.3390/genes11121513
- 570 45. Grosz BR, Tisch S, Tchan MC, et al. A novel synonymous KMT2B variant in a patient
571 with dystonia causes aberrant splicing. *Mol Genet Genomic Med.* 2022;10(5).
572 doi:10.1002/MGG3.1923
- 573 46. Mutai H, Wasano K, Momozawa Y, et al. Variants encoding a restricted carboxy-
574 terminal domain of SLC12A2 cause hereditary hearing loss in humans. *PLoS Genet.*
575 2020;16(4). doi:10.1371/journal.pgen.1008643
- 576 47. Knapp KM, Sullivan R, Murray J, et al. Linked-read genome sequencing identifies
577 biallelic pathogenic variants in DONSON as a novel cause of Meier-Gorlin syndrome.
578 *J Med Genet.* 2020;57(3):195-202. doi:10.1136/jmedgenet-2019-106396
- 579 48. Starokadomskyy P, Gemelli T, Rios JJ, et al. DNA polymerase- α regulates the
580 activation of type I interferons through cytosolic RNA:DNA synthesis. *Nat Immunol.*
581 2016;17(5):495-504. doi:10.1038/ni.3409
- 582 49. Varga L, Danis D, Skopkova M, et al. Novel EYA4 variant in Slovak family with late
583 onset autosomal dominant hearing loss: A case report. *BMC Med Genet.* 2019;20(1).
584 doi:10.1186/s12881-019-0806-y

- 585 50. Legendre M, Rodriguez-Ballesteros M, Rossi M, et al. CHARGE syndrome: A
586 recurrent hotspot of mutations in CHD7 IVS25 analyzed by bioinformatic tools and
587 minigene assays /631/208 /692/308 brief-communication. *European Journal of Human*
588 *Genetics*. 2018;26(2):287-292. doi:10.1038/s41431-017-0007-0
- 589 51. Abdulhay NJ, Fiorini C, Verboon JM, et al. Impaired human hematopoiesis due to a
590 cryptic intronic GATA1 splicing mutation. *Journal of Experimental Medicine*.
591 2019;216(5):1050-1060. doi:10.1084/jem.20181625
- 592 52. Kishore S, Khanna A, Stamm S. Rapid generation of splicing reporters with
593 pSpliceExpress. *Gene*. 2008;427(1-2):104-110. doi:10.1016/j.gene.2008.09.021
- 594 53. Pedersen BS, Bhetariya PJ, Brown J, et al. Somalier: rapid relatedness estimation for
595 cancer and germline studies using efficient genome sketches. *Genome Med*.
596 2020;12(1):62. doi:10.1186/s13073-020-00761-2
- 597 54. Pais LS, Snow H, Weisburd B, et al. seqr: A web-based analysis and collaboration tool
598 for rare disease genomics. *Hum Mutat*. 2022;43(6):698-707.
599 doi:10.1002/HUMU.24366
- 600 55. Stark Z, Foulger RE, Williams E, et al. Scaling national and international improvement
601 in virtual gene panel curation via a collaborative approach to discordance resolution.
602 *Am J Hum Genet*. 2021;108(9):1551-1557. doi:10.1016/j.ajhg.2021.06.020
- 603 56. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting Splicing
604 from Primary Sequence with Deep Learning. *Cell*. 2019;176(3):535-548.e24.
605 doi:10.1016/j.cell.2018.12.015
- 606 57. Payne A, Holmes N, Clarke T, Munro R, Debebe BJ, Loose M. Readfish enables
607 targeted nanopore sequencing of gigabase-sized genomes. *Nat Biotechnol*.
608 2021;39(4):442-450. doi:10.1038/s41587-020-00746-x
- 609 58. Stevanovski I, Chintalaphani SR, Gamaarachchi H, et al. Comprehensive genetic
610 diagnosis of tandem repeat expansion disorders with programmable targeted nanopore
611 sequencing. *Sci Adv*. 2022;8(9). doi:10.1126/SCIADV.ABM5386
- 612 59. Gamaarachchi H, Samarakoon H, Jenner SP, et al. Fast nanopore sequencing data
613 analysis with SLOW5. *Nat Biotechnol*. 2022;40(7):1026-1029. doi:10.1038/s41587-
614 021-01147-4
- 615 60. Samarakoon H, Ferguson JM, Jenner SP, et al. Flexible and efficient handling of
616 nanopore sequencing signal data with slow5tools. *Genome Biol*. 2023;24(1):69.
617 doi:10.1186/s13059-023-02910-3
- 618 61. Li H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics*.
619 2018;34(18):3094-3100. doi:10.1093/bioinformatics/bty191
- 620 62. Zheng Z, Li S, Su J, Leung AWS, Lam TW, Luo R. Symphonizing pileup and full-
621 alignment for deep learning-based long-read variant calling. *Nat Comput Sci*.
622 2022;2(12):797-803. doi:10.1038/s43588-022-00387-x

- 623 63. Martin M, Patterson M, Garg S, et al. WhatsHap: fast and accurate read-based phasing.
624 Published online 2016. doi:10.1101/085050
- 625 64. Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative Genomics Viewer. *Nat*
626 *Biotechnol.* 2011;29(1):24. doi:10.1038/NBT.1754
- 627 65. Zeng Z, Bromberg Y. Predicting Functional Effects of Synonymous Variants: A
628 Systematic Review and Perspectives. *Front Genet.* 2019;0:914.
629 doi:10.3389/FGENE.2019.00914
- 630 66. Kishore Jaganathan A, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting
631 Splicing from Primary Sequence with Deep Learning In Brief A deep neural network
632 precisely models mRNA splicing from a genomic sequence and accurately predicts
633 noncoding cryptic splice mutations in patients with rare genetic diseases. Predicting
634 Splicing from Primary Sequence with Deep Learning. *Cell.* 2018;176:535-548.
635 doi:10.1016/j.cell.2018.12.015
- 636 67. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic
637 variation. *Nucleic Acids Res.* 2001;29(1):308-311. Accessed March 5, 2019.
638 <http://www.ncbi.nlm.nih.gov/pubmed/11125122>
- 639 68. Chen S, Francioli LC, Goodrich JK, et al. A genomic mutational constraint map using
640 variation in 76,156 human genomes. *Nature.* 2024;625(7993):92-100.
641 doi:10.1038/s41586-023-06045-0
- 642 69. All of Us Research Program Investigators, Denny JC, Rutter JL, et al. The “All of Us”
643 Research Program. *N Engl J Med.* 2019;381(7):668-676. doi:10.1056/NEJMs1809937
- 644 70. Taliun D, Harris DN, Kessler MD, et al. Sequencing of 53,831 diverse genomes from
645 the NHLBI TOPMed Program. *Nature.* 2021;590(7845):290-299. doi:10.1038/s41586-
646 021-03205-y
- 647 71. Kent WJ. <tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool. *Genome*
648 *Res.* 2002;12(4):656-664. doi:10.1101/gr.229202
- 649 72. Castle JC. SNPs occur in regions with less genomic sequence conservation. *PLoS One.*
650 2011;6(6):e20660. doi:10.1371/journal.pone.0020660
- 651 73. Boisson M, Arrondel C, Cagnard N, et al. A wave of deep intronic mutations in X-
652 linked Alport syndrome. *Kidney Int.* 2023;104(2):367-377.
653 doi:10.1016/j.kint.2023.05.006
- 654 74. Qian X, Wang J, Wang M, et al. Identification of Deep-Intronic Splice Mutations in a
655 Large Cohort of Patients With Inherited Retinal Diseases. *Front Genet.*
656 2021;12:647400. doi:10.3389/fgene.2021.647400
- 657 75. Di Scipio M, Tavares E, Deshmukh S, et al. Phenotype Driven Analysis of Whole
658 Genome Sequencing Identifies Deep Intronic Variants that Cause Retinal Dystrophies
659 by Aberrant Exonization. *Invest Ophthalmol Vis Sci.* 2020;61(10):36.
660 doi:10.1167/iovs.61.10.36

- 661 76. Xie Z, Sun C, Liu Y, et al. Practical approach to the genetic diagnosis of unsolved
662 dystrophinopathies: a stepwise strategy in the genomic era. *J Med Genet.*
663 2021;58(11):743-751. doi:10.1136/jmedgenet-2020-107113
- 664 77. Zaum AK, Stüve B, Gehrig A, et al. Deep intronic variants introduce DMD
665 pseudoexon in patient with muscular dystrophy. *Neuromuscul Disord.* 2017;27(7):631-
666 634. doi:10.1016/j.nmd.2017.04.003
- 667 78. Anna A, Monika G. Splicing mutations in human genetic disorders: examples,
668 detection, and confirmation. *J Appl Genet.* 2018;59(3):253-268. doi:10.1007/s13353-
669 018-0444-7
- 670 79. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of
671 sequence variants: A joint consensus recommendation of the American College of
672 Medical Genetics and Genomics and the Association for Molecular Pathology.
673 *Genetics in Medicine.* 2015;17(5):405-424. doi:10.1038/gim.2015.30
- 674 80. Depondt C, Donatello S, Rai M, et al. MME mutation in dominant spinocerebellar
675 ataxia with neuropathy (SCA43). *Neurol Genet.* 2016;2(5):e94.
676 doi:10.1212/NXG.0000000000000094
- 677 81. Kim J, Woo S, de Gusmao CM, et al. A framework for individualized splice-switching
678 oligonucleotide therapy. *Nature.* 2023;619(7971):828-836. doi:10.1038/s41586-023-
679 06277-0
- 680 82. Chen S, Heendeniya SN, Le BT, et al. Splice-Modulating Antisense Oligonucleotides
681 as Therapeutics for Inherited Metabolic Diseases. *BioDrugs.* 2024;38(2):177-203.
682 doi:10.1007/s40259-024-00644-7
- 683 83. Santos JI, Gonçalves M, Matos L, et al. Splicing Modulation as a Promising
684 Therapeutic Strategy for Lysosomal Storage Disorders: The Mucopolysaccharidoses
685 Example. *Life.* 2022;12(5):608. doi:10.3390/life12050608
- 686 84. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of
687 Duchenne muscular dystrophy. *Ann Neurol.* 2013;74(5):637-647.
688 doi:10.1002/ana.23982
- 689 85. Frank DE, Schnell FJ, Akana C, et al. Increased dystrophin production with golodirsen
690 in patients with Duchenne muscular dystrophy. *Neurology.* 2020;94(21):e2270-e2282.
691 doi:10.1212/WNL.00000000000009233
- 692 86. Heo YA. Golodirsen: First Approval. *Drugs.* 2020;80(3):329-333.
693 doi:10.1007/s40265-020-01267-2
- 694 87. Clemens PR, Rao VK, Connolly AM, et al. Safety, Tolerability, and Efficacy of
695 Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53
696 Skipping: A Phase 2 Randomized Clinical Trial. *JAMA Neurol.* 2020;77(8):982-991.
697 doi:10.1001/jamaneurol.2020.1264
- 698 88. Shirley M. Casimersen: First Approval. *Drugs.* 2021;81(7):875-879.
699 doi:10.1007/s40265-021-01512-2

- 700 89. Wurster CD, Winter B, Wollinsky K, et al. Intrathecal administration of nusinersen in
701 adolescent and adult SMA type 2 and 3 patients. *J Neurol*. 2019;266(1):183-194.
702 doi:10.1007/s00415-018-9124-0
- 703 90. Osredkar D, Jílková M, Butenko T, et al. Children and young adults with spinal
704 muscular atrophy treated with nusinersen. *Eur J Paediatr Neurol*. 2021;30:1-8.
705 doi:10.1016/j.ejpn.2020.11.004
- 706 91. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham Control in Later-
707 Onset Spinal Muscular Atrophy. *N Engl J Med*. 2018;378(7):625-635.
708 doi:10.1056/NEJMoa1710504
- 709 92. Bianchi L, Sframeli M, Vantaggiato L, et al. Nusinersen Modulates Proteomics
710 Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients. *Int J Mol*
711 *Sci*. 2021;22(9). doi:10.3390/ijms22094329
- 712 93. Kim J, Woo S, de Gusmao CM, et al. A framework for individualized splice-switching
713 oligonucleotide therapy. *Nature*. 2023;619(7971):828-836. doi:10.1038/s41586-023-
714 06277-0
- 715 94. Kim J, Hu C, Moufawad El Achkar C, et al. Patient-Customized Oligonucleotide
716 Therapy for a Rare Genetic Disease. *N Engl J Med*. 2019;381(17):1644-1652.
717 doi:10.1056/NEJMoa1813279
- 718 95. Yamada M, Maeta K, Suzuki H, et al. Successful skipping of abnormal pseudoexon by
719 antisense oligonucleotides in vitro for a patient with beta-propeller protein-associated
720 neurodegeneration. *Sci Rep*. 2024;14(1):6506. doi:10.1038/s41598-024-56704-z
- 721 96. Aguti S, Bolduc V, Ala P, et al. Exon-Skipping Oligonucleotides Restore Functional
722 Collagen VI by Correcting a Common COL6A1 Mutation in Ullrich CMD. *Mol Ther*
723 *Nucleic Acids*. 2020;21:205-216. doi:10.1016/J.OMTN.2020.05.029
- 724 97. Kim J, Hu C, Moufawad El Achkar C, et al. Patient-Customized Oligonucleotide
725 Therapy for a Rare Genetic Disease. *N Engl J Med*. 2019;381(17):1644-1652.
726 doi:10.1056/NEJMoa1813279
- 727 98. Dominov JA, Uyan Ö, McKenna Yasek D, et al. Correction of pseudoexon splicing
728 caused by a novel intronic dysferlin mutation. *Ann Clin Transl Neurol*. 2019;6(4):642-
729 654. doi:10.1002/acn3.738
- 730 99. Martínez-Pizarro A, Leal F, Holm LL, et al. Antisense Oligonucleotide Rescue of
731 Deep-Intronic Variants Activating Pseudoexons in the 6-Pyruvoyl-Tetrahydropterin
732 Synthase Gene. *Nucleic Acid Ther*. 2022;32(5):378-390. doi:10.1089/nat.2021.0066
- 733

Table 1. Phenotypic characterization of individuals with recessive CMT *MME* variants reported in this manuscript. Abbreviations- AFO: Ankle foot orthoses; CMTNS: Charcot-Marie-Tooth Neuropathy Score; UL/LL: Upper Limb/Lower Limb

Family #	Family 1				Family 2
Individual	V:1	V:3	V:4	V:6	II:1
Sex	M	F	M	M	F
Onset	Fourth decade	Childhood	Childhood	Childhood	Early-adult
Age at evaluation (years)	60-65	65-70	65-70	65-70	50-55
Presenting symptom	Gait unsteadiness	Difficulty running	Difficulty sitting on crossed legs during childhood	Difficulty running, multiple ankle sprains	Bilateral leg weakness and sensory disturbance
Atrophy UL/LL	Yes/yes	Yes/yes	Yes/yes	Yes/yes	No/Yes (left calf only)
Foot deformity	None	Pes cavus/hammer toes	-	Pes cavus	Pes cavus
Tone UL/LL	Normal/reduced	Normal/normal	Normal, increased		Normal/normal
Shoulder abduction	5	5	3	5	4
Elbow flexion	4	5	3	4	5
Elbow extension	4	5	3	4	5

Finger abduction	2	4	3	1	4
Hip flexion	4	3	3	3	4
Knee extension	4	3	3	4	4
Knee flexion	4	3	3	4	4
Ankle dorsiflexion	0	0	3	1	3
Ankle plantarflexion	0	0	3	0	4
Deep tendon reflexes UL/LL	Absent/absent	Absent ankle	Hyperreflexia knee, absent ankle	Absent/absent	Normal/ reduced ankle reflexes
Plantars	Absent	-	Absent	Flexor	Flexor
Proprioception UL/LL	Normal/reduced to the MTP	-	-	Normal/reduced to the ankle	Normal/reduced to ankle
Vibration UL/LL	Normal/reduced to ankle	Absent in toes	-	Reduced to wrist/reduced to knees	Reduced to mid-shin
Pinprick UL/LL	Normal/reduced to ankle	Normal/reduced to the mid shin	Reduced to elbows/reduced to knees	Reduced to PIP joint/reduced to knees	Reduced to mid-shin Reduced dorsum hand
Temperature sensation UL/LL	Normal/reduced to ankle	-	-	Reduced to wrist/reduced to above	Reduced to mid-shin





				knee	
Other symptoms/signs	Cough	GORD and cough	Corticospinal tract signs	Nil	Fatty infiltration on left gastrocnemius
Gait	High steppage/ataxic	High steppage/ataxic	Steppage gait	High steppage/ataxic	High steppage
Romberg's sign	Positive	Positive		Positive	Mild sway
Mobility aids	AFO, walking stick and mobility scooter	AFO, walker	AFO, walker, mobility scooter	Wheelchair	AFO, elbow crutch
CMTNS (version 2)	31	-	28/36	36	15



Table 2. Nerve conduction study (NCS) findings of individuals with recessive CMT *MME* variants reported in this manuscript. Abbreviations: APB: abductor pollicis brevis; ADM: abductor digiti minimi; EDB: extensor hallucis brevis; FHB: flexor hallucis brevis; CMAP: compound motor action potential; CV: conduction velocity; NR: no response; SNAP: sensory nerve action potential; R: right, L:left.

Family #	Family 1		Family 2
Individual	V:1	V:6	II:1
Age at NCS (years)	60-65	65-70	55-60
Median nerve (digit II) [orthodromic(R)]			
SNAP (uV)	NR	NR	6.6
CV (m/s)	NR	NR	50
Ulnar nerve (digit V) [orthodromic(R)]			
SNAP (uV)	NR	1	4.9
CV (m/s)	NR	40.2	51
Sural nerve [orthodromic(R)]			
SNAP (uV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Sural nerve [orthodromic(L)]			



SNAP (uV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Median nerve (APB) (R)			
CMAP (mV)	NR	NR	4.8
CV (m/s)	NR	NR	41
Ulnar nerve (ADM) (R)			
CMAP (mV)	2	0.6	6.6
CV (m/s)	44.4	44.7	52 (wrist-below elbow) 57 (wrist-above elbow)
Peroneal nerve (EDB) (R)			
CMAP (mV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Tibial nerve (FHB) (L)			
CMAP (mV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Needle EMG	Absent voluntary units in the right tibialis anterior and medial gastrocnemius muscles, as well as denervation-reinnervation changes in	Absent recruitment of motor units in the right tibialis anterior, medial gastrocnemius, first dorsal interosseous and vastus lateralis	Reduced recruitment of motor units in the right tibialis interior and right vastus medialis muscles. Discrete recruitment of muscle fibres in the

	the right vastus lateralis muscle.	muscles. Denervation-reinnervation changes were evident in the right deltoid, biceps brachii and triceps brachii muscles.	right gastrocnemius muscle.
--	------------------------------------	---	-----------------------------

a**b****c****d**

a**i.**

medRxiv preprint doi: <https://doi.org/10.1101/2024.04.22.24306048>; this version posted April 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

ii.**b****c****d**